A detailed history of Royal Bank Of Canada transactions in Nuvalent, Inc. stock. As of the latest transaction made, Royal Bank Of Canada holds 15,894 shares of NUVL stock, worth $1.34 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares
15,894
Previous 13,063 21.67%
Holding current value
$1.34 Million
Previous $990,000 64.14%
% of portfolio
0.0%
Previous 0.0%

Shares

14 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

BUY
$67.44 - $112.17 $190,922 - $317,553
2,831 Added 21.67%
15,894 $1.63 Million
Q2 2024

Aug 14, 2024

BUY
$62.76 - $81.61 $152,883 - $198,801
2,436 Added 22.92%
13,063 $990,000
Q1 2024

Nov 05, 2024

SELL
$72.35 - $88.99 $176,244 - $216,779
-2,436 Reduced 18.65%
10,627 $797,000
Q1 2024

May 15, 2024

BUY
$72.35 - $88.99 $10,346 - $12,725
143 Added 1.36%
10,627 $797,000
Q4 2023

Feb 14, 2024

BUY
$42.42 - $80.28 $317,344 - $600,574
7,481 Added 249.12%
10,484 $771,000
Q3 2023

Nov 14, 2023

BUY
$39.12 - $49.85 $57,506 - $73,279
1,470 Added 95.89%
3,003 $138,000
Q2 2023

Aug 14, 2023

BUY
$23.58 - $44.68 $9,384 - $17,782
398 Added 35.07%
1,533 $64,000
Q1 2023

May 15, 2023

SELL
$25.42 - $33.52 $41,866 - $55,207
-1,647 Reduced 59.2%
1,135 $29,000
Q4 2022

Feb 14, 2023

BUY
$18.46 - $36.37 $47,552 - $93,689
2,576 Added 1250.49%
2,782 $82,000
Q3 2022

Nov 14, 2022

BUY
$13.55 - $19.92 $1,504 - $2,211
111 Added 116.84%
206 $4,000
Q2 2022

Aug 15, 2022

SELL
$7.4 - $15.07 $7,622 - $15,522
-1,030 Reduced 91.56%
95 $1,000
Q1 2022

May 16, 2022

SELL
$11.65 - $19.57 $14,096 - $23,679
-1,210 Reduced 51.82%
1,125 $16,000
Q4 2021

Feb 14, 2022

BUY
$18.01 - $30.1 $18,946 - $31,665
1,052 Added 82.0%
2,335 $45,000
Q3 2021

Nov 15, 2021

BUY
$18.25 - $38.35 $23,414 - $49,203
1,283 New
1,283 $29,000

Others Institutions Holding NUVL

About Nuvalent, Inc.


  • Ticker NUVL
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 42,977,800
  • Market Cap $3.62B
  • Description
  • Nuvalent, Inc., a clinical stage biopharmaceutical company, develops therapies for patients with cancer. Its lead product candidates are NVL-520, a brain-penetrant ROS1-selective inhibitor to inhibit ROS1 fusions that express the normal ROS1 kinase domain without any drug-resistant mutations and remain active in the presence of mutations conferr...
More about NUVL
Track This Portfolio

Track Royal Bank Of Canada Portfolio

Follow Royal Bank Of Canada and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Royal Bank Of Canada, based on Form 13F filings with the SEC.

News

Stay updated on Royal Bank Of Canada with notifications on news.